Alexander Rau | Senior Scientist Protein Engineering
Anaveon
Alexander joined Anaveon in 2022 as a protein engineer, focused on developing the next generation of antibody-cytokine fusion proteins for cancer therapy. He previously worked at a biotech company, focusing on the generation of antibody therapeutics for immuno-oncology. He also has a strong academic background in cancer cell biology and antibody engineering, with the aim of overcoming resistance mechanisms. His main expertise is in developing bispecific antibodies, from screening binders from various sources, designing, cloning, producing and purifying them, to characterizing and testing them in vitro and in vivo.
Appearances:
Festival of Biologics Day 1 @ 15:40
ANV700: A Proximity-Activated IL-21 Therapeutic Targeting PD-1+ Tumor Infiltrating Lymphocytes
- Targeted IL-21 delivery: ANV700 is a Proximity-Activated Cytokine (PAC) that selectively delivers IL-21 to PD-1+ tumor-antigen specific T cells, maintaining strong IL-21 signaling in PD-1+ cells while minimizing off-target activation and systemic toxicity.
- Enhanced Tumor-Specific CD8 T Cell Activity: In mouse tumor models, ANV700 surrogate compound treatment leads to tumor growth retardation by increasing the number and functionality of tumor antigen-specific CD8 T cells.
- Synergistic Therapeutic Potential: ANV700 synergizes with PD-1 checkpoint inhibitors and PD-1-targeted IL-2Rβγ agonists, combining proliferative and reinvigorating effects for a durable anti-tumor response, supporting its development as a monotherapy or combination therapy.
Created by
Terrapinn is proud to be a member of isla.
Working together to build sustainable events